The conceptive shift of therapeutic strategy for prolactinomas
10.3781/j.issn.1000-7431.2024.2401-0016
- VernacularTitle:垂体泌乳素细胞腺瘤治疗策略的理念改变
- Author:
Zhebao WU
1
;
Yijun CHENG
;
Yazhuo ZHANG
Author Information
1. 上海交通大学医学院附属瑞金医院神经外科,上海 200025
- Publication Type:Journal Article
- Keywords:
Pituitary neuroendocrine tumors;
Prolactinomas;
Dopamine agonists;
Endoscopic transnasal surgery;
Pituitary Tumor Centers of Excellence
- From:
Tumor
2024;44(9):901-904
- CountryChina
- Language:Chinese
-
Abstract:
Prolactinomas are the most common subtype of pituitary neuroendocrine tumors(PitNETs),which can be treated with drugs surgery,radiotherapy and so on.For invasive and non-invasive prolactinomas,there is still controversy on the treatment choice of drugs or surgery as the first-line option.In the past decade,with the progress of endoscopic transsphenoidal minimally invasive technology in-depth understanding of PitNETs pseudocapsule,and constructions of Pituitary Tumor Centers of Excellence(PTCOE),the biochemical remission rate by surgical treatment has been significantly improved.For some specific subtypes of prolactinomas,such as microadenomas and enclosed macroadenomas(Knosp grade 0-2),the biochemical remission rate can achieve 90％with the treatment of endoscopic transsphenoidal surgery,which was similar with the drug efficacy.Therefore,the International Pituitary Society made the latest consensus statement on the clinical treatment of prolactinomas suggested that surgery can be performed as first-line option for some selected prolactinomas.This shift of therapeutic strategy was determined in the form of consensus statement,which has a strong clinical guiding significance.
